>>> Europe : Brokers Upgrades & Downgrades - 5th of September 2025 V3(++)

>>> Up
* Amazon Raised to Buy at Punto Casa de Bolsa
* ASML Raised to Buy at UBS
* Avantium Raised to Hold at Kepler Cheuvreux; PT 13.50 euros (++)
* Enento Group Raised to Accumulate at Inderes; PT 17 euros
* Generali Raised to Outperform at Mediobanca SpA; PT 37 euros
* HarbourVest Global Raised to Overweight at Barclays
* HSBC Raised to Outperform at BNPP Exane; PT 1,100 pence
* Huber+Suhner PT Raised to 140 Swiss francs at UBS (++)
* MFE Raised to Buy at Equita; PT 5 euros (+)
* QPR Software Raised to Reduce at Inderes; PT 58 euro cents
* Sartorius Raised to Buy at Stifel; PT 230 euros
* SGS Raised to Outperform at BNPP Exane; PT 98 Swiss francs (+)
* STMicro Raised to Outperform at BNPP Exane; PT 26 euros
* STMicro ADRs Raised to Outperform at BNPP Exane

>>> Down
* Abivax Cut to Hold at Portzamparc; PT 63 euros (+)
* Admiral Cut to Sell at Peel Hunt; PT 2,350 pence
* Apax Global Alpha Cut to Equal-Weight at Barclays; PT 165 pence
* BioArctic Cut to Sell at Nordea; PT 220 kronor
* BioMerieux Cut to Neutral at Invest Securities SA; PT 124 euros (++)
* DKSH Cut to Underperform at BNPP Exane; PT 55 Swiss francs
* Genus Cut to Hold at Kepler Cheuvreux; PT 2,700 pence (++)
* HgCapital Cut to Equal-Weight at Barclays; PT 570 pence
* Jet2 PT Cut to 1,800 pence from 1,920 pence at Panmure Liberum (+)
* NatWest Cut to Underperform at BNPP Exane; PT 520 pence
* NB PE Partners Cut to Underweight at Barclays; PT 1,510 pence

>>> Initiation
* Hermes ADRs Rated New Outperform at BNPP Exane; PT $326.60
* Ralph Lauren Rated New Buy at William O'Neil
* Ninety One Rated New Buy at SBG Securities; PT 221 pence (+)
* Sixt Rated New Buy at UBS; PT 102 euros (+)

>>> Call
* Admiral Falls After Cut to Sell at Peel Hunt; PT 2,350 pence (++)
* ASML Raised to Buy at UBS; Says Negative Factors Priced In (+)
* Sanofi Selloff Overdone, Valuation Highly Attractive: Berenberg (+
* Sixt New Buy at UBS on Margin Recovery, US Market-Share Gains

>>> US Research Calls

Research Calls
  • Upgrades
    • ASML (ASML) upgraded to Buy from Neutral at UBS
    • Crown Holdings (CCK) upgraded to Buy from Hold at Truist, tgt $118
    • Duluth Holdings (DLTH) upgraded to Outperform from Neutral at Robert W. Baird, tgt $7
    • Healthcare Realty Trust (HR) upgraded to Outperform from Sector Perform at Scotiabank, tgt $20
    • State Street (STT) upgraded to Buy from Neutral at Citigroup, tgt $130
  • Downgrades
    • BYD (BYDDY) downgraded to Hold from Buy at Erste Group
    • Credicorp (BAP) downgraded to Hold from Buy at HSBC, tgt $255
    • FirstCash (FCFS) downgraded to Hold from Buy at Loop Capital, tgt $145
    • J.B. Hunt Transport Services (JBHT) downgraded to Neutral from Buy at UBS, tgt $157
    • Knight-Swift (KNX) downgraded to Neutral from Buy at UBS, tgt $51
    • Lululemon Athletica (LULU) downgraded to Neutral from Buy at BofA Securities, tgt $210
    • Lululemon Athletica (LULU) downgraded to Perform from Outperform at Oppenheimer
    • Lululemon Athletica (LULU) downgraded to Market Perform from Outperform at Telsey Advisory, tgt $200
    • Lululemon Athletica (LULU) downgraded to In Line from Outperform at Evercore ISI, tgt $180
    • Lululemon Athletica (LULU) downgraded to Market Perform from Outperform at William Blair
    • Lululemon Athletica (LULU) downgraded to Hold from Buy at Stifel, tgt $205
    • NiSource (NI) downgraded to Hold from Buy at Jefferies, tgt $44
    • Schneider National (SNDR) downgraded to Neutral from Buy at UBS, tgt $26
  • Others
    • Avalo Therapeutics (AVTX) initiated with a Buy at TD Cowen
    • Blue Owl Capital (OBDC) initiated with a Buy at Clear Street, tgt $15
    • Blue Owl Technology Finance (OTF) initiated with a Hold at Clear Street, tgt $15
    • Capital Southwest (CSWC) initiated with a Hold at Clear Street, tgt $22
    • Chagee Holdings (CHA) initiated with a Neutral at Macquarie, tgt $19
    • Crescent Capital BDC (CCAP) initiated with a Buy at Clear Street, tgt $16.50
    • Dolby Laboratories (DLB) initiated with a Neutral at Robert W. Baird, tgt $74
    • Duolingo (DUOL) initiated with a Neutral at Robert W. Baird, tgt $280
    • Enerpac Tool Group (EPAC) initiated with a Buy at Roth Capital, tgt $48
    • Eos Energy Enterprises (EOSE) initiated with a Hold at Jefferies, tgt $6.50
    • ESAB (ESAB) initiated with a Buy at Roth Capital, tgt $150
    • Fannie Mae (FNMA) initiated with a Neutral at B. Riley, tgt $10
    • Fidus Investment (FDUS) initiated with a Buy at Clear Street, tgt $21
    • Gladstone Capital (GLAD) initiated with a Hold at Clear Street, tgt $25.50
    • Gladstone Investment (GAIN) initiated with a Buy at Clear Street, tgt $14.50
    • Great Elm Capital (GECC) initiated with a Buy at Clear Street, tgt $11.50
    • Hinge Health (HNGE) initiated with a Neutral at Robert W. Baird, tgt $56
    • Karman Holdings (KRMN) initiated with a Strong Buy at Raymond James, tgt $100
    • Lincoln Electric (LECO) initiated with a Buy at Roth Capital, tgt $279
    • Lionsgate Studios (LION) initiated with an Outperform at Robert W. Baird, tgt $8
    • Omada Health (OMDA) initiated with a Neutral at Robert W. Baird, tgt $24
    • QXO Inc. (QXO) initiated with an Outperform at Raymond James, tgt $28
    • Revolution Medicines (RVMD) initiated with a Buy at Truist, tgt $99
    • Runway Growth Finance (RWAY) initiated with a Hold at Clear Street, tgt $11
    • Saratoga Investment (SAR) initiated with a Hold at Clear Street, tgt $24
    • Sixth Street Specialty Lending (TSLX) initiated with a Hold at Clear Street, tgt $22
    • Starz Entertainment (STRZ) initiated with a Neutral at Robert W. Baird, tgt $13
    • State Street (STT) assumed with a Buy at Citigroup, tgt $130
    • TKO Group (TKO) initiated with an Outperform at Robert W. Baird, tgt $225
    • TJX Companies (TJX) reinstated with a Buy at Erste Group
    • Twilio (TWLO) initiated with a Buy at Rosenblatt, tgt $140
    • UiPath (PATH) assumed with a Neutral at DA Davidson, tgt $12
    • Waystar Holding (WAY) initiated with an Outperform at Robert W. Baird, tgt $44

>>> US Early Pre-Market Gappers

  • Gapping up:
    • BRZE +18.9%, GWRE +13.9%, IOT +11%, TTAN +10%, AVGO +9.6%, API +9.1%, ZUMZ +8.9%, BILL +8.8%, DOCU +8.1%, MIR +5.8%, PATH +5.8%, HCM +5.3%, EMX +4.7%, BBCP +4.3%, DEFT +4%, CLPT +3.8%, BMNR +3.6%, SG +2.9%, PONY +2.9%, MAX +2.7%, OKLO +2.7%, MARA +1.8%, TRTX +1.8%, VZLA +1.4%, COHR +1.3%, CIFR +1.2%, EWZ +1.1%
  • Gapping down:
    • LULU -17.9%, LFVN -16.6%, NX -14.9%, CURV -12.7%, MYGN -11.5%, PHR -11.1%, AGX -6.2%, AMBQ -4.2%, FFAI -3.7%, CPRT -2.7%, SFD -1.5%, ZEPP -1.3%, OBIO -1.1%, HHH -0.9%, DNA -0.9%, AIR -0.8%

>>> Europe : Brokers Upgrades & Downgrades - 5th of September 2025 V2(+)

>>> Up
* Amazon Raised to Buy at Punto Casa de Bolsa
* ASML Raised to Buy at UBS
* Enento Group Raised to Accumulate at Inderes; PT 17 euros
* Generali Raised to Outperform at Mediobanca SpA; PT 37 euros
* HarbourVest Global Raised to Overweight at Barclays
* HSBC Raised to Outperform at BNPP Exane; PT 1,100 pence
* MFE Raised to Buy at Equita; PT 5 euros (+)
* QPR Software Raised to Reduce at Inderes; PT 58 euro cents
* Sartorius Raised to Buy at Stifel; PT 230 euros
* SGS Raised to Outperform at BNPP Exane; PT 98 Swiss francs (+)
* STMicro Raised to Outperform at BNPP Exane; PT 26 euros
* STMicro ADRs Raised to Outperform at BNPP Exane

>>> Down
* Abivax Cut to Hold at Portzamparc; PT 63 euros (+)
* Admiral Cut to Sell at Peel Hunt; PT 2,350 pence
* Apax Global Alpha Cut to Equal-Weight at Barclays; PT 165 pence
* BioArctic Cut to Sell at Nordea; PT 220 kronor
* DKSH Cut to Underperform at BNPP Exane; PT 55 Swiss francs
* HgCapital Cut to Equal-Weight at Barclays; PT 570 pence
* Jet2 PT Cut to 1,800 pence from 1,920 pence at Panmure Liberum (+)
* NatWest Cut to Underperform at BNPP Exane; PT 520 pence
* NB PE Partners Cut to Underweight at Barclays; PT 1,510 pence

>>> Initiation
* Hermes ADRs Rated New Outperform at BNPP Exane; PT $326.60
* Ralph Lauren Rated New Buy at William O'Neil
* Ninety One Rated New Buy at SBG Securities; PT 221 pence (+)
* Sixt Rated New Buy at UBS; PT 102 euros (+)

>>> Call
* ASML Raised to Buy at UBS; Says Negative Factors Priced In (+)
* Sanofi Selloff Overdone, Valuation Highly Attractive: Berenberg (+
* Sixt New Buy at UBS on Margin Recovery, US Market-Share Gains

FT : Ørsted cuts profit outlook blaming slower summer wind speeds

Ørsted cuts profit outlook blaming slower summer wind speeds
Bad news comes as Danish renewable energy group moves to shore up balance sheet after Trump blocks key US project

Ørsted blamed lower-than-normal wind speeds in July and August for a cut in its annual profit guidance, as the troubled Danish renewable energy group prepared to ask shareholders for three-quarters of its market value in new capital.

The world’s largest offshore wind developer said it now expected earnings before interest, tax, depreciation and amortisation this year to be DKr24bn-DKr27bn ($3.8bn-$4.2bn), down from a previous DKr25bn-DKr28bn.

It said that lower wind speeds during the summer months compared with the rest of 2025 had cost it DKr1.2bn while an additional DKr300mn hit was caused by a delay of almost a year at a Taiwanese wind farm.

It last confirmed its previous guidance on August 11, raising questions about the credibility of its new management team led by chief executive Rasmus Errboe, who was promoted after its previous leader was ousted in January.

The latest bad news comes as the Danish group prepares for an emergency shareholder meeting on Friday to approve a DKr60bn rights issue made necessary by US President Donald Trump’s hostility to wind power.

Ørsted said on Thursday that it would sue his administration over a stop-work order issued last month on Revolution Wind, an almost-complete wind farm meant to provide power for 350,000 homes in the north-east of the US.

The group already faced difficulty selling down its 100 per cent stake in another offshore wind project, Sunrise Wind, prompting it to shore up its balance sheet. Its market capitalisation on Thursday was DKr84bn, close to a record low.

Ørsted’s rights issue is backed by its two largest shareholders, the Danish state and Norwegian oil and gas group Equinor, which own 50 per cent and 10 per cent, respectively. Norway’s $2tn oil fund, which has a 3 per cent stake, has also backed the capital raising, which is expected to take place at a big discount.

The Danish group — which has previously warned, including in 2021, that low wind speeds have hurt profits — once had the ambition to become the world’s first renewable energy supermajor.

But it has been hit by major issues at its US projects that have already led to writedowns, as well as rising interest rates and problems in the supply chain.

FT : Robert Kennedy grilled over vaccine scepticism in fiery US Senate hearing

Robert Kennedy grilled over vaccine scepticism in fiery US Senate hearing
Trump officials defend health secretary after sharp questioning from Republican and Democratic lawmakers

Senators grilled US health secretary Robert F Kennedy Jr in a contentious hearing in Washington on Thursday that piled pressure on Donald Trump’s appointee over his vaccine scepticism.

In a combative three-hour back-and-forth with the Senate finance committee, Kennedy defended last week’s firing of the director of the Centers for Disease Control and Prevention, Susan Monarez, as well as his approach to shaping vaccine policy.

Kennedy faced sharp questioning from three Republican senators, as well as Democratic lawmakers, in a signal of growing discontent within the president’s party over his pick for health secretary.

Louisiana Republican Bill Cassidy, a medical doctor, sparred with Kennedy over access to Covid-19 vaccines. The Food and Drug Administration last week approved a new round of such vaccines, but set new limits on who can get the jabs.

“I would say, effectively, we are denying people vaccine,” Cassidy told Kennedy.

“You’re wrong,” Kennedy shot back.

Cassidy also expressed concerns about Kennedy’s nominees for the CDC’s vaccine advisory panel, which makes recommendations about vaccine dosages for Americans and the age they should be administered.

Cassidy noted many of Kennedy’s picks had been paid for serving as expert witnesses for plaintiff’s attorneys suing vaccine makers.

“If we put people who are paid witnesses for people suing vaccines that actually seems like a conflict of interest,” Cassidy said. “Do you agree with that?”

Kennedy replied that the individuals might be biased in their opinions, but “it is not a financial conflict of interest”.

John Barrasso, the Republican senator from Wyoming and the number-two ranking Republican in the Senate leadership, also vented frustration with Kennedy.

“In your confirmation hearings, you promised to uphold the highest standards for vaccines,” said Barrasso, who is also a trained physician. “Since then, I’ve grown deeply concerned.”

Barrasso said vaccines for measles and hepatitis B “could be in jeopardy” under Kennedy’s leadership, adding: “That would put Americans at risk and reverse decades of progress.”

Republican Thom Tillis of North Carolina pushed Kennedy to explain why he fired Monarez.

Earlier on Thursday, Monarez alleged she was pressed to preapprove certain recommendations from the vaccine advisory panel, which is filled with Kennedy’s allies. Earlier this year, the health secretary fired the entire committee.

While opinion polls show declining levels of public trust in health agencies and institutions, surveys find the vast majority of Americans believe the benefits of vaccines outweigh any risks.

Nevertheless, vaccine scepticism has surged in recent years. On Wednesday, Florida’s surgeon-general Joseph Ladapo and Republican governor Ron DeSantis set out plans to become the first state to end all vaccine mandates, including requirements for children attending school.

The White House has consistently defended Kennedy, who has pushed a “Make America Healthy Again” agenda that has targeted not only pharmaceutical companies but also the food and drinks industries.

White House press secretary Karoline Leavitt said in a post on X on Thursday that the health secretary was “taking flak because he’s over the target”.

“The Trump administration is addressing root causes of chronic disease, embracing transparency in government and championing gold-standard science,” Leavitt said. “Only the Democrats could attack that common sense effort.”

Vice-president JD Vance also defended Kennedy after Thursday’s hearing, attacking the senators who criticised him.

“When I see all these senators trying to lecture and ‘gotcha’ Bobby Kennedy today all I can think is: You all support off-label, untested, and irreversible hormonal ‘therapies’ for children, mutilating our kids and enriching big pharma,” Vance wrote, in a reference to Democratic lawmakers’ support for gender-affirming care for transgender minors.

“You’re full of shit and everyone knows it,” the vice-president added.

FT : Luxury watch prices diverge as auctions test collector appetites

Luxury watch prices diverge as auctions test collector appetites
Retailers see a widening split in the pre-owned market


At its flagship Geneva sale on November 8, Phillips will offer a steel Patek Philippe Reference 1518 that the house last knocked-down in 2016 for the then unprecedented sum of SFr11mn ($13.7mn), making it the first wristwatch to break the eight-figure barrier and the most valuable at auction until the sale of Hollywood star Paul Newman’s Rolex Cosmograph for $17.8mn the following year.

But in the nine years since the last sale of the watch that Phillips describes as a “unicorn” — just four steel-cased Reference 1518s were produced — many areas of the pre-owned market have soared to stratospheric levels before experiencing an equally marked decline that only now appears to be stabilising.

So the question that’s likely to intrigue many collectors during the next two months concerns whether the 82-year-old perpetual calendar chronograph can meet or exceed its record-breaking 2016 price — or whether its anonymous owner will have to come to terms with taking a significant hit.

At Sotheby’s New York in June, a Patek Philippe Reference 2499 (the successor to the 1518) crossed the block for $4.3mn — a sobering 40 per cent drop from the $7.6mn the house sold it for at a Hong Kong auction in 2022.

<

Although an extreme example of declining values in the blue-chip sector of the market, it is representative of the Covid-induced boom in pre-owned watch sales having entered a steep decline in the spring of 2022 and continuing until the end of last year.

Ross Crane, co-founder of the data and tech-driven pre-owned trading site Subdial, says the rapid rise in prices during 2020 and 2021 encouraged both established and speculative dealers to pay “tomorrow’s prices” for watches simply to be able to secure stock that they knew they could resell quickly.

“That dealer-driven market put off many end users for two years or more, because they didn’t know where values were going and were afraid to buy a watch that, ultimately, they might end up losing a lot of money on,” says Crane. “But the recent return to stability is definitely giving people the confidence to start buying again.”

However, according to WatchCharts (another platform that tracks prices and sales trends) the pre-owned values of dozens of other brands such as IWC, Jaeger-LeCoultre, Blancpain and Panerai are still on the slide — with Audemars Piguet’s market index dropping by 4.9 per cent in a year and Vacheron Constantin’s by 11.3 per cent.

For Aurel Bacs, the independent watch consultant who works in association with Phillips and is overseeing November’s Geneva sale, it is unrealistic to take a blanket view of the pre-owned market in simple “up or down” terms.

“As an industry, I don’t believe we can talk about one pre-owned watch market,” he says. “It would be like two people in a pub talking about the global real estate market and comparing a villa in St Moritz with a skyscraper in Beijing, a mall in Texas and a private island in the Caribbean. They are all completely different, just as watches can be divided into periods, types, designs, complications and so on.”

Bacs’s point about an uneven landscape is echoed in the experience of Paul Altieri, whose California-based pre-owned watch business Bob’s Watches focuses predominantly on Rolex. Operating since 2010, Bob’s Watches maintains an inventory worth $5-10mn and typically turns over $5mn annually.

Contrary to some sectors of the pre-owned market, Altieri says demand for the Rolex pieces in which he specialises has been exceptionally strong of late, partly coinciding with the US imposing a 39 per cent tariff on Swiss imports.

“July is normally slow due to vacations, but this year we were 36 per cent up on 2024 and are around 20 per cent up on sales overall,” says Altieri.

“I thought the tariff situation would take a few weeks to get resolved, but it looks as though it’s going to go on for a while and that could certainly push buyers from the primary to the pre-owned market — Rolex sends about half of its new product to the US and there is now probably $100bn worth of pre-owned inventory in the country.”

Altieri says the fact that tight controls mean authorised Rolex dealers only have a few weeks’ supply and were unable to “bulk-up” their stock as a buffer prior to the tariff kicking in is likely to further increase the already strong demand for pre-owned.

On the other side of the Atlantic, Charlie Walker, founder of UK business The Luxury Watch Company based in North Yorkshire, also specialises in popular Rolex models in “as new” condition with the brand accounting for more than 80 per cent of the firm’s inventory.

“There has been a market correction, but the appetite for Rolex is still very strong and people are happy to pay 10, 15 or even 30 per cent above retail for a pre-owned piece — it’s a no-brainer, because they can get the watch they want immediately without having to develop a relationship with an authorised dealer, often by buying other watches that they don’t really want.”

But, Walker says other major brands are sticking. “Many watches produced by recognised brands such as Breitling, Omega, Jaeger-LeCoultre and so on have always [underperformed] on the secondary market and can still be had at a 20-25 per cent discount from new.”

At the higher end, he cites models such as Vacheron Constantin’s steel, blue dial, “boutique only” Overseas Self-Winding model as having fallen from being sought-after on the pre-owned market to now selling for well under the £24,800 list price — and the once difficult to obtain Audemars Piguet Royal Oak self-winding with slate grey dial — once fetching as much as £65,000 on the grey market — now commanding less than £30,000.

“The appetite is just not there for those and there are a lot available, so we rarely stock them — when it comes to some brands and some models, it really is a buyer’s market.”